Navigation Links
CryoLife to Present at 25th Annual Piper Jaffray Healthcare Conference
Date:11/25/2013

ATLANTA, Nov. 25, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at The New York Palace Hotel in New York City.

A live webcast of the Company's presentation is scheduled to begin at 3:00 p.m. ET and will feature a brief overview of the company by D. Ashley Lee, executive vice president, chief operating officer and chief financial officer, followed by a question and answer session.  

The live webcast can be accessed through CryoLife's website, www.cryolife.com, on the Investor Relations page.  An archived copy of the webcast will be available for 90 days on the same website.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.

Contacts:

CryoLife                                                                                   The Ruth Group  
D. Ashley Lee                                                                            Nick Laudico / Zack Kubow
Executive Vice President, Chief Financial Officer                           646-536-7030 / 7020
and Chief Operating Officer                                                          nlaudico@theruthgroup.com
Phone: 770-419-3355
                                                                  zkubow@theruthgroup.com


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  Akcea Therapeutics, a subsidiary of ... of a Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx ... The goal of the study is to determine the ... in a planned Phase 3 cardiovascular outcome study. ... Akcea,s strategic collaboration with Novartis to develop and commercialize ...
(Date:3/30/2017)... March 30, 2017  Purcell Julie & Lefkowitz LLP, a ... investigating a potential breach of fiduciary duty claim involving the ... SGYP ). If you are a shareholder ... regarding this investigation, free of charge, please visit us at: ... ...
(Date:3/29/2017)... 2017 Wound care devices and products are ... wound. The industry mainly consists of establishments engaged in ... of wounds caused by mechanical, chemical, thermal, and radiogenic ... as diabetes, skin related diseases, immunological diseases, and other ... was the largest region in the wound care devices ...
Breaking Medicine Technology:
(Date:3/29/2017)... Diego, CA (PRWEB) , ... March 29, 2017 , ... ... and up to 300,000 people each year develop other types of metastatic brain tumors(3). ... quickly throughout the brain(3). As efforts focus on finding more effective treatment options, the ...
(Date:3/29/2017)... ... 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , ... Center will serve as the official title sponsor of the Baltimore Women’s Classic, the ... thousands of women will walk or run the course around the Baltimore Inner Harbor. ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... several educational opportunities for attending prescribers at the upcoming World Congress, in Hollywood ... “A4M has always been recognized as the visionary leader in the training of ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or ... teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
Breaking Medicine News(10 mins):